investment-strategies

The 0100 Europe gathering on April 21–23 remains one of Europe's most pragmatic venues for GP-LP relationships and private markets deal talk.

A pragmatic 2026 map of NYC's most active seed and pre-seed investors — and what they actually fund.

With 13,000+ attendees and 500+ LPs expected in Helsinki, Slush 2026 remains the gravity center of European venture deal-making.

BDC Capital's life sciences venture fund bolsters Canadian therapeutics and medtech — an underrated pipeline for U.S. and EU follow-on rounds.

Jeito Capital's €1B Fund II cements the case that Europe can fund late-stage biopharma domestically, without exporting all growth-stage capital to the U.S.

Blackstone's opportunistic private credit fund is not VC, but its scale directly changes how venture-backed companies refinance, recapitalize, and exit.